Retatrutide is an investigational peptide that works as a triple receptor agonist, engaging the GLP-1, GIP and glucagon receptors at the same time. It's currently in clinical trials and is not an approved medicine.
Most single-mechanism metabolic peptides act on just one receptor. Retatrutide draws research interest precisely because it spans three pathways at once — something preclinical and trial research has examined around appetite signalling, glucose handling and energy expenditure.
Because it's unlicensed and investigational, retatrutide sits squarely in the research-compound category. It shouldn't be confused with approved, prescription-only products, and the research literature stays the right reference point.
Vosberg supplies retatrutide as a lyophilised powder in several vial strengths, each HPLC-verified to at least 99% purity with a batch certificate on request.
This article is for educational and research-reference purposes only. It is not medical advice. All products are supplied strictly for in-vitro laboratory research use, not for human or veterinary consumption.
